[{"NetIncomeLoss_1_Q3_USD":-10048000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":17961802.0,"CommitmentsAndContingencies_0_Q3_USD":null,"LiabilitiesNoncurrent_0_Q3_USD":1123000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":5285000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":-1267000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":18829000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q3_USD":1648000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":60000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q3_USD":156000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":17905926.0,"AssetsCurrent_0_Q3_USD":62504000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_3_Q3_USD":26814000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q3_USD":419000.0,"ForeignCurrencyTransactionGainLossRealized_3_Q3_USD":441000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3_Q3_USD":45692000.0,"CommonStockSharesIssued_0_Q3_shares":18021224.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":32584000.0,"Assets_0_Q3_USD":66206000.0,"OtherComprehensiveIncomeLossNetOfTax_3_Q3_USD":615000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":689000.0,"MarketableSecuritiesRealizedGainLoss_3_Q3_USD":192000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":3560000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":10472000.0,"OperatingLeaseLiability_0_Q3_USD":1715000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":29409000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":9097000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":2064000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":-539000.0,"ProceedsFromStockPlans_3_Q3_USD":161000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":7289000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":2171000.0,"CommonStockValue_0_Q3_USD":18000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":397000.0,"ForeignCurrencyTransactionGainLossBeforeTax_3_Q3_USD":715000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q3_USD":301000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":1809000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-30673000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-9359000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-1182000.0,"OtherAssetsNoncurrent_0_Q3_USD":181000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":17727000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":1123000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":212694000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":-217000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-48000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":1653000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q3_USD":193000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":1648000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3_Q3_USD":192000.0,"CommonStockSharesOutstanding_0_Q3_shares":18021224.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":83000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":1241000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3_Q3_USD":1024000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q3_USD":813000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-19126000.0,"StockIssuedDuringPeriodValueEmployeeBenefitPlan_1_Q3_USD":55000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q3_USD":17332000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q3_USD":658000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":1938000.0,"LiabilitiesCurrent_0_Q3_USD":6518000.0,"NonoperatingIncomeExpense_3_Q3_USD":8593000.0,"NonoperatingIncomeExpense_1_Q3_USD":2609000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":4604000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_Q3_USD":426000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q3_USD":436000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":124000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":17727000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":1868000.0,"NetIncomeLoss_3_Q3_USD":-31288000.0,"AccountsPayableCurrent_0_Q3_USD":641000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-152880000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":32561000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":49000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1_Q3_USD":76000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q3_USD":349000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q3_USD":156000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":-35000.0,"CommonStockSharesAuthorized_0_Q3_shares":100000000.0,"OperatingIncomeLoss_3_Q3_USD":-39881000.0,"OperatingIncomeLoss_1_Q3_USD":-12657000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":32584000.0,"InvestmentIncomeInterest_3_Q3_USD":589000.0,"InvestmentIncomeInterest_1_Q3_USD":137000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":66206000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":2238000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":3677000.0,"AmortizationOfDebtDiscountPremium_3_Q3_USD":247000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":592000.0,"OperatingExpenses_3_Q3_USD":39881000.0,"OperatingExpenses_1_Q3_USD":12657000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-1.75,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.56,"ProfitLoss_3_Q3_USD":-31288000.0,"StockholdersEquity_0_Q3_USD":58565000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"AccruedProfessionalFeesCurrent_0_Q3_USD":251000.0,"Ticker":"KALV","CIK":"1348911","name":"KALVISTA PHARMACEUTICALS, INC.","OfficialName":"KalVista Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210131","fy":"2021.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"339433230.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210311"}]